KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Acquisitions (2016)

Travere Therapeutics' Acquisitions history spans 3 years, with the latest figure at $115000.0 for Q4 2016.

  • For Q4 2016, Acquisitions changed N/A year-over-year to $115000.0; the TTM value through Dec 2017 reached $115000.0, down 81.3%, while the annual FY2020 figure was $95.3 million, N/A changed from the prior year.
  • Acquisitions reached $115000.0 in Q4 2016 per TVTX's latest filing, down from $500000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $33.4 million in Q1 2015 to a low of $115000.0 in Q4 2016.
  • Average Acquisitions over 3 years is $15.8 million, with a median of $14.8 million recorded in 2014.
  • The largest YoY upside for Acquisitions was 14.68% in 2015 against a maximum downside of 14.68% in 2015.
  • A 3-year view of Acquisitions shows it stood at $29.2 million in 2014, then rose by 14.68% to $33.4 million in 2015, then tumbled by 99.66% to $115000.0 in 2016.
  • Per Business Quant, the three most recent readings for TVTX's Acquisitions are $115000.0 (Q4 2016), $500000.0 (Q2 2016), and $33.4 million (Q1 2015).